Ting Wu

Mrs. Ting Wu

Guangdong Provincial Key Laboratory of Drug Screening, School of Pharmaceutical Sciences, Southern Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Phytomedicine
Verified
Journal Article
Closed access
YCYanyu Chen
Yanyu Chen
ZZZean Zhao
Zean Zhao
YLYongmei Li
Yongmei Li
YYYang Yang
Yang Yang
LLLu Li
Lu Li
JPJianxin Pang
Jianxin Pang

14 October 2019 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
YDYue Dong
Yue Dong
TZTong Zhao
Tong Zhao
WAWei Ai
Wei Ai
WZWaleed A. Zalloum
Waleed A. Zalloum
DKDongwei Kang
Dongwei Kang
PZPeng Zhan
Peng Zhan
Introduction: Human urate transporter 1 (URAT1), which is an influx transporter protein, is located at the apical surface of renal tubular cells and presumed to be the major transporter responsible for the reabsorption of urate from blood. About 90% of patients develop hyperuricemia due to insufficient urate excretion, thus it is important to develop URAT1 inhibitors that could enhance renal urate excretion by blocking the reabsorption of urate anion. Areas covered: In this review, the authors addressed the patent applications (2016-2019) about URAT1 inhibitors and some medicinal chemistry strategies employed in these patents. Expert opinion: Substituent decorating, bioisosterism, and scaffold hopping are three common medicinal chemistry strategies used in the discovery of URAT1 inhibitors. Meanwhile, the introduction of sulfonyl group into small molecules has become one of the important strategies for structural optimization of URAT1 inhibitors. Furthermore, developing drug candidates targeting both URAT1 and xanthine oxidase (XOD) has attracted lots of interest and attention.

25 March 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
ZZZe-An Zhao
Ze-An Zhao
YJYu Jiang
Yu Jiang
YCYan-Yu Chen
Yan-Yu Chen
TWTing Wu
Ting Wu
QLQun-Sheng Lan
Qun-Sheng Lan
JPJianxin Pang
Jianxin Pang

2 November 2022 in Foods
Verified
Journal Article
Open access
PDF file
YLYongmei Li
Yongmei Li
LLLu Li
Lu Li
JTJinhong Tian
Jinhong Tian
FZFengxin Zheng
Fengxin Zheng
HLHui Liao
Hui Liao
TWTing Wu
Ting Wu
Hyperuricemia (HUA), characterized by abnormal serum uric acid (UA) levels, is recognized as an important risk factor for hyperuricemic nephropathy (HN), which is strongly linked to gut microbiota. This study investigated the protective effects and regulatory mechanisms of insoluble fiber from barley leaves (BL) against HN, induced by adenine (Ad) and potassium oxonate (PO). The results showed that BL dramatically reduced the levels of serum UA and creatinine (CR) and alleviated renal injury and fibrosis. Moreover, BL modulated oxidative stress and downregulated the expression of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) in the kidneys of mice with HN. In addition, the 16S rRNA sequence data showed that BL also increased the relative abundance of short-chain fatty acids (SCFAs)-producing bacteria, including Bacteroides, Alloprevotella, and Eisenbergiella. Besides, BL treatment also increased SCFAs levels. Of interest, the application of SCFAs in hyperuricemic mice effectively reduced their serum UA. Furthermore, SCFAs dose-dependently inhibited URAT1 and GLUT9 in vitro and potently interacted with URAT1 and GLUT9 in the docking analysis. When taken together, our results indicate that BL and its metabolite SCFAs may be potential candidates for relieving HUA or HN.

30 March 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YLYongmei Li
Yongmei Li
FZFengxin Zheng
Fengxin Zheng
SZShiqi Zhong
Shiqi Zhong
KZKunlu Zhao
Kunlu Zhao
HLHui Liao
Hui Liao
JPJianxin Pang
Jianxin Pang

1 March 2021 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
YCYanyu Chen
Yanyu Chen
ZZZean Zhao
Zean Zhao
YLYongmei Li
Yongmei Li
LLLu Li
Lu Li
YJYu Jiang
Yu Jiang
JPJianxin Pang
Jianxin Pang
Glucose transporter 9 (GLUT9), which transports urate in an electrogenic and voltage-dependent manner, plays an important role in the maintenance of normal blood uric acid/urate levels. In the present study, we established a cell model based on the single-electrode patch-clamp technique for characterization of GLUT9 and explored the inhibitory effects of benzobromarone (BM) and probenecid (PB) on urate-induced currents in mouse GLUT9a (mGLUT9a)–expressing HEK-293T cells. The results showed that uric acid, rather than glucose perfusion, led to a rapid and large outward current by mGLUT9a in dose-, voltage-, and pH-dependent manners. BM prominently and irreversibly inhibited the uric acid–induced currents through mGLUT9a, and PB weakly and reversibly inhibited mGLUT9a. We found that depletion of K+ in the external solution significantly strengthened the blockade of BM on mGLUT9a. In addition, an enhanced inhibitory rate of BM was detected when the pH of the external solution was changed from 7.4 to 5.5, indicating that BM functions optimally in an acidic environment. In conclusion, the combination of the established cell model with patch-clamp techniques first revealed the function properties of GLUT9 inhibitors and may provide potential benefits to the study of GLUT9 inhibitors as antihyperuricemic or antigout agents.